IRMD

This article first appeared on GuruFocus. Release Date: May 01, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. iRadimed Corp (NASDAQ:IRMD) reported a 13% increase in revenue for Q1 2026, reaching $22 million compared to the same period in 2025. The company achieved a 33% improvement in operating income, totaling $7.2 million, driven by disciplined expense management and a modified commission structure. Net income rose by 22% to $5.8 million, or $0.45 per diluted share, showcasing strong financial performance. The new 3,870 MR IV pump system is experiencing higher-than-expected ASP increases, with initial orders showing a 20% lift over the previous model. iRadimed Corp (NASDAQ:IRMD) is targeting a $50 million annual revenue run rate for pumps, with expectations of achieving a $100-plus million revenue run rate as 2026 progresses. Revenue expectations for Q2 2026 are projected to be between $20 million to $21 million, indicating a potential decline from Q1 2026. The company is facing challenges in ramping up production of the new 3,870 pump system, with a cautious approach to scaling manufacturing. Despite strong initial interest, Q2 revenue will not fully reflect the high level of order activity due to production constraints. The effective tax rate for the quarter increased to approximately 25%, influenced by the timing of deductions tied to equity grants. The company anticipates a controlled revenue growth rather than a step change, with declining revenue from older pump systems offsetting new product sales. Warning! GuruFocus has detected 2 Warning Sign with IRMD. Is IRMD fairly valued? Test your thesis with our free DCF calculator. Q: Why are customers transitioning from single or dual-channel systems to ordering four-channel systems? A: Roger Soucy, President and CEO, explained that more than half of the orders have been for the quad system, which was unexpected. The sales team has effectively demonstrated the benefits of the new system, which is smaller and stacks easily on a pole. Customers have realized the need for additional channels based on past experiences, leading to increased orders for the quad stack. Q: Is there a financial incentive for customers to purchase four-channel systems? A: Roger Soucy clarified that there is no specific financial incentive for purchasing four-channel systems...

Revenue growth of 13% was primarily driven by the fulfillment of the 3860 pump backlog and steady performance in MRI patient monitoring. Operating income improved by 33% due to disciplined expense management and a modified commission structure that optimized sales costs. The launch of the 3870 MRI IV pump is seeing initial Average Selling Price (ASP) increases of approximately 20%, significantly exceeding the previously anticipated 10% to 14% range. A strategic shift in customer behavior is emerging where a majority of new orders are for 'Quad' 4-pump systems, effectively doubling the pump channels per site compared to legacy 2-channel systems. Management identifies a substantial replacement opportunity of approximately 6,400 legacy units over five years old as the primary growth engine for the next several years. The company is intentionally managing a 'controlled ramp' for the 3870 to stabilize the supply chain and production quality, rather than pursuing an immediate step-change in volume. Management targets a $100 million-plus annual revenue run rate as 2026 progresses, supported by higher 3870 ASPs and increased channel volume. The company expects to sell over 2,000 3870 pump channels annually in the domestic market, aiming for a $50 million annual run rate for the pump segment alone. Q2 2026 revenue guidance of $20 million to $21 million reflects a transition period where declining legacy 3860 sales are offset by the initial 130 to 135 unit shipments of the 3870. The back half of 2026 is expected to show accelerated performance as 3870 production scales and higher-value bookings are realized. The effective tax rate is projected to trend downward by year-end as windfall deductions for equity grants vest in the fourth quarter. R&D expenses increased due to the cessation of capitalized software for the 3870 and ongoing development of next-generation monitoring systems. The company declared a $0.20 per share quarterly cash dividend, maintaining its commitment to capital return alongside growth initiatives. Supply chain stabilization and 'ramping up know-how' are cited as the primary reasons for the conservative production schedule in the first half of the year. Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management attributes the shift to the 3870's...

Strong quarter and raised guidance: iRadimed posted its 16th consecutive quarter of record revenue, with Q2 sales up 14% to $20.4M and GAAP EPS of $0.45, and raised full‑year 2025 revenue guidance to $80.0M–$82.5M (GAAP EPS $1.60–$1.70). MRidium 3870 clearance could be transformational: FDA clearance for the MRidium 3870 is expected to drive a replacement cycle (management cites over 6,200 U.S. 3860 channels eligible) and support a path toward a $100M revenue run rate, with ASPs ~12% higher than the legacy pump. Near‑term rollout is staged with an elevated backlog: iRadimed has a record backlog and will deploy only a small number of 3870 units in Q4 for feedback, warning of weaker pump bookings in Q1 2026 during the transition before bookings accelerate later in the year. Interested in iRadimed Corporation? Here are five stocks we like better. iRadimed (NASDAQ:IRMD) reported second-quarter 2025 results that management said marked the company’s 16th consecutive quarter of record revenues, driven by strength in its MRI-compatible infusion pump business and continued growth in patient monitoring. For the quarter ended June 30, 2025, revenue rose 14% year over year to $20.4 million, while gross margin held steady at 78%. GAAP diluted earnings per share increased 18% to $0.45, according to CFO Jack Glenn. President and CEO Roger Susi highlighted the quarter’s performance as the company prepares to launch its newly cleared MRidium 3870 IV pump system. → Corning Beats Q1 Estimates but Drops 9% on Guidance Miss Glenn said the revenue increase was “driven by strong performance across all product lines,” led by infusion pumps and patient monitoring. MRI-compatible IV infusion pump systems: $8.2 million, up 19% year over year Patient vital signs monitoring systems: $5.9 million, up 9% Disposables: $4.2 million, up 14% on increased utilization Domestic revenue rose 18% to $18.2 million, while international sales declined 9% to $2.2 million. Domestic revenue represented 89% of total revenue in the quarter, compared with 86% in the prior-year period, Glenn said. → Meta Posted Its Best Sales Growth Since 2021—So Why Did Shares Fall? Gross profit was $16.0 million, up 14% from $14.0 million a year earlier, with gross margin “consistent with the prior year.” Glenn said margin performance benefited from “increased overhead absorption as we built inventory ahead of the new fac...

ORLANDO, Fla. (AP) — ORLANDO, Fla. (AP) — IRadimed Corp. (IRMD) on Friday reported net income of $5.8 million in its first quarter. The Orlando, Florida-based company said it had profit of 45 cents per share. Earnings, adjusted for stock option expense, were 49 cents per share. The maker of IV devices that can be used in MRI machines posted revenue of $22 million in the period. For the current quarter ending in June, iRadimed expects its per-share earnings to range from 44 cents to 48 cents. The company said it expects revenue in the range of $20 million to $21 million for the fiscal second quarter. IRadimed expects full-year earnings in the range of $2.06 to $2.21 per share, with revenue ranging from $91 million to $96 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IRMD at https://www.zacks.com/ap/IRMD

Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025. Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the first quarter of 2026, which are increases of 22% and 17%, respectively, compared to the same period in 2025. Declares a regular quarterly cash dividend of $0.20 per share of common stock for the second quarter of 2026, payable on May 29, 2026. ORLANDO, Fla., May 01, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD) announced today its financial results for the three months ended March 31, 2026. The Company is a leader in developing innovative magnetic resonance imaging (“MRI”) compatible medical devices and products. The Company is a provider of (i) non-magnetic intravenous (“IV”) infusion pump systems and (ii) a non-magnetic patient vital signs monitoring system that are each designed for use during MRI procedures. “We are pleased to report a strong start to 2026, with first-quarter revenue of $22.0 million, a 13% increase over the same period last year. Our continued revenue growth, combined with disciplined expense management, drove operating income of $7.2 million — a 33% improvement over the first quarter of 2025 — and net income of $5.8 million, or $0.45 per diluted share, a 22% increase over the first quarter 2025. "Beyond our financial results, the first quarter was a significant milestone for Iradimed with the commercial launch of our next-generation 3870 MRI-compatible IV infusion pump system. Customer reception has been very encouraging, with tremendous interest and strong early order activity. Notably, early order sizes have exceeded those typical of the prior-generation platform, reinforcing our confidence in the 3870's value proposition. We expect significant shipments to begin in the second quarter of 2026 as we transition our customers to the new platform, with the third quarter reflecting the full impact of 3870 shipments and revenue growth accelerating through the back half of the year. We remain focused on delivering innovative solutions for patients and healthcare providers while generating strong returns for our stockholders,” said Roger Susi, President and Chief Ex...

Iradimed (IRMD) reported Q1 non-GAAP earnings of $0.49 per diluted share, up from $0.42 a year earli

iRadimed (IRMD) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.42 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +8.89%. A quarter ago, it was expected that this maker of IV devices that can be used in MRI machines would post earnings of $0.49 per share when it actually produced earnings of $0.54, delivering a surprise of +10.2%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. iRadimed, which belongs to the Zacks Medical - Instruments industry, posted revenues of $21.98 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.61%. This compares to year-ago revenues of $19.51 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. iRadimed shares have lost about 14.2% since the beginning of the year versus the S&P 500's gain of 5.3%. While iRadimed has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for iRadimed was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of toda...

ORLANDO, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 first quarter financial results before the market opens on Friday, May 1, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI7676b33322324840ad2b154cc8e65b88. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-time via the internet at http://www.iradimed.com/en-us/investors/events/. A recording of the call will be available on the Company’s website following the completion of the call. About IRADIMED CORPORATION IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging (“MRI”) compatible medical devices. We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan. Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 syste...

On February 17, 2026, Nine Ten Capital Management disclosed selling 342,907 shares of IRadimed (NASDAQ:IRMD), an estimated $29.42 million trade based on quarterly average pricing. According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Nine Ten Capital Management reduced its position in IRadimed by 342,907 shares during the fourth quarter. The estimated value of the shares sold is approximately $29.42 million, calculated using the average closing price for the quarter. The quarter-end position value decreased by $13.21 million, reflecting both the share sale and changes in the company’s share price. Nine Ten Capital Management’s IRadimed stake now represents 13.2% of its 13F reportable assets following the sale. Top five holdings after the filing: NASDAQ: MGNI: $48.75 million (15.4% of AUM) NYSE: GPGI: $46.64 million (14.8% of AUM) NASDAQ: CLBT: $44.71 million (14.2% of AUM) NASDAQ: AGYS: $43.17 million (13.7% of AUM) NASDAQ: IRMD: $41.68 million (13.2% of AUM) As of February 16, 2026, IRadimed shares were priced at $99.81, up 83.0% over the past year and outperforming the S&P 500 by 71.21 percentage points. IRadimed develops and markets MRI-compatible medical devices, including infusion pump systems and patient vital signs monitors, along with related accessories and services The company generates revenue primarily through direct sales and distribution of proprietary medical equipment and consumables to healthcare facilities It serves hospitals, acute care facilities, and outpatient imaging centers in the United States and internationally IRadimed specializes in MRI-compatible medical devices, offering a focused product portfolio that addresses safety and operational needs in imaging environments. The company leverages a direct sales model and an established distribution network to reach a broad base of healthcare providers. When a concentrated fund trims a double-digit position after a huge run, it is usually about discipline, not panic. IRadimed just delivered its 18th consecutive quarter of record revenue, posting $22.7 million in fourth quarter sales, up 17% year over year, and full year revenue of $83.8 million. GAAP EPS climbed to $1.75 for 2025, and management raised its quarterly dividend to $0.20 from $0.17, signaling confidence in cash generation. Yet the stock is up 83% over the past year and now represents 13.2% o...

Achieved 18th consecutive quarter of record revenue, driven by strong performance in legacy infusion pumps and patient monitoring systems. Strategic decision to limit extended maintenance to pumps under 7 years old successfully accelerated the replacement cycle, contributing to 20% growth in the legacy 3860 model. Identified a significant domestic replacement opportunity of approximately 6,400 pump channels over 5 years old, which serves as the primary growth catalyst for the next several years. Positioned the new 3870 pump with a 10% to 14% average selling price (ASP) increase, reflecting modernized design and improved user interface. Management expects the 3870 to penetrate greenfield opportunities more effectively and increase utilization among existing customers who previously used pumps sporadically. Confidence in reaching a $100 million-plus annual revenue run rate during 2026 is supported by higher ASPs, increased replacement volume, and growth in the monitoring business. The general sales release for the 3870 pump is scheduled for April 2026, following an intensive clinical support and monitoring phase with initial pilot users. Anticipate shipping approximately 100 to 130 3870 pump channels in April, with bookings expected to ramp significantly in the second half of 2026. Targeting the replacement of an additional 1,000 pump channels per year starting in Q2 2026 to address the aging domestic installed base. Revenue in the first half of 2026 will be sustained by the MRI monitoring business and the existing 3860 pump backlog during the 3870 transition. International expansion for the 3870 remains on track with CE Mark expected by late 2026 and Japan clearance projected for summer 2027. Inventory levels increased in Q4 2025 as the company stockpiled 3870 components in anticipation of the large-scale launch. Management is actively managing the 'challenge' of transitioning production and inventory from the legacy 3860 to the new 3870 model during Q2 2026. Gross margins are expected to remain stable in the first half of 2026, with potential expansion in the second half driven by higher volumes and increased ASPs. The company has already initiated R&D for a next-generation MRI monitor, targeting a 2028 market launch to maintain its product lifecycle momentum. Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you inve...

This article first appeared on GuruFocus. Revenue (Q4 2025): $22.7 million, up 17% year-over-year. Full Year Revenue (2025): $83.8 million, up 14% year-over-year. GAAP Diluted EPS (Q4 2025): $0.50, up 25%. Non-GAAP Diluted EPS (Q4 2025): $0.54, up 23%. GAAP Diluted EPS (Full Year 2025): $1.75, up 17%. Non-GAAP Diluted EPS (Full Year 2025): $1.93, up 16%. Gross Margin (Q4 2025): 75%. Gross Margin (Full Year 2025): Approximately 77%. Operating Expenses (Q4 2025): $9.9 million. Operating Expenses (Full Year 2025): $38.2 million. Net Income (Q4 2025): $6.4 million. Net Income (Full Year 2025): $22.5 million. Cash and Cash Equivalents (End of 2025): $51.2 million. Cash Flow from Operations (Q4 2025): $5.9 million. Cash Flow from Operations (Full Year 2025): $24.9 million. Warning! GuruFocus has detected 7 Warning Sign with IRMD. Is IRMD fairly valued? Test your thesis with our free DCF calculator. Release Date: February 10, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. iRadimed Corp (NASDAQ:IRMD) achieved its 18th consecutive quarter of record revenue, with Q4 2025 revenue reaching $22.7 million, a 17% increase over Q4 2024. The company reported strong growth across all product lines, including a 20% year-over-year increase in MRI-compatible IV infusion pump systems and a 7.5% increase in patient vital signs monitoring systems. Gross margins remained robust at approximately 77% for the year and 75% for Q4 2025. The new 3870 MRI IV pump is expected to drive significant revenue growth, with anticipated ASP increases of 10% to 14% and a large replacement opportunity. iRadimed Corp (NASDAQ:IRMD) ended the year with a strong cash position, holding $51.2 million in cash and cash equivalents, and generated $24.9 million in cash flow from operations for the full year. The company faces challenges in managing the transition from the 3860 to the 3870 pump, which could impact inventory levels and sales. Operating expenses increased to $9.9 million for the quarter and $38.2 million for the full year, reflecting higher general and administrative costs. The effective tax rate for the year was 20.7%, which, although lower than the previously estimated 22%, still represents a significant expense. The regulatory process for the 3870 pump in Europe and Japan is expected to take time, with CE Mark clearance anticipated by...